TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05543954
Drug: 68Ga-RGD
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
Study: NCT05919017
Drug: Naltrexone implant
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone implant
Study: NCT05022186
Drug: Cannabidiol Oil
Normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will use it with specific instructions and they will be monitored at least one time in a month
Study: NCT05983107
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
Study: NCT05983107
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
Study: NCT05983107
Drug: Ovarian function suppression(OFS)
Normalized name: plasma protein fraction Injection [Plasmanate]
DrugBank: Plasma protein fraction (human) (DB13968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
Study: NCT06344403
Drug: analgesic
Normalized name: Analgesic
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.
Study: NCT06318104
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
Study: NCT06318104
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
Study: NCT00021008
Drug: picoplatin
Normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05578326
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
Study: NCT05578326
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.2 mg/m2, over 60 minutes at day 1 of each cycle
Study: NCT06055179
Drug: Xiao Chai Hu Tang (XCHT)
Normalized name: Xiao mai
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Study: NCT06055179
Drug: Irinotecan regimen
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks.
Study: NCT05176964
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
Study: NCT05265975
Drug: ATG-010
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
Study: NCT05265975
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration,QD, Days 1-21 of each cycle
Study: NCT05265975
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection Days 1 of each cycle, Cycles 1-6
Study: NCT04778644
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral gel capsule CBD
Study: NCT04838639
Drug: NO-13065
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.
Study: NCT04868162
Drug: MRG003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06073860
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: According to the approved label
Study: NCT05085327
Drug: ChapStick Lip Moisturizer Black Cherry
DrugBank: Cherry (DB10518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05804071
Drug: Niferex
Normalized name: Niferex
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions
Study: NCT04268706
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
Study: NCT04268706
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
Study: NCT05129748
Drug: Sodium Thiosulfate + Mannitol
Normalized name: Sodium Thiosulfate
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
Study: NCT04896528
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment.
Study: NCT04906278
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
Study: NCT05488366
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04996524
Drug: epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
Study: NCT05642793
Drug: proactive Anti-VEGF (conbercept) use
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
Study: NCT05642793
Drug: passive Anti-VEGF (conbercept) use
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Study: NCT05627791
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
Study: NCT06462053
Drug: PD-1 antibody (Toripalimab)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240mg d1 q3w
Study: NCT06462053
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study: NCT06727019
Drug: Atropine (0.01%)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine eye drops at concentration of 0.01%
Study: NCT06727305
Drug: Sirolimus 0.5 Mg Oral Tablet
Normalized name: sirolimus 0.5 MG Oral Tablet
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT06727305
Drug: Sirolimus 1Mg Oral Tablet
Normalized name: Sirolimus 1mg Oral tablet
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT06727305
Drug: Sirolimus 2 MG Oral Tablet
Normalized name: sirolimus 2 MG Oral Tablet
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT06727305
Drug: Everolimus 0.5 MG Oral Tablet
Normalized name: EVEROLIMUS 0.5 mg ORAL TABLET
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT06727305
Drug: Everolimus 1 MG Oral Tablet
Normalized name: everolimus 1 MG Oral Tablet
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT06727305
Drug: Everolimus 2 MG Oral Tablet
Normalized name: EVEROLIMUS 2 mg ORAL TABLET
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
Study: NCT03943615
Drug: Voxelotor
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04988841
Drug: MaaT013
Normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
Study: NCT04988841
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
Study: NCT04988841
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AntiPD1 ( immunothérapy)
Study: NCT04988841
Drug: MoviPrep
Normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
Study: NCT04988841
Drug: Placebo of Maat013
DrugBank: MaaT013 (DB18648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: expérimental drug placebo of MaaT013
Study: NCT05687253
Drug: Rocuronium Bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Rocuronium
Study: NCT06327698
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable solution
Study: NCT06327698
Drug: anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT05712941
Drug: Lerociclib
Normalized name: Lerociclib
DrugBank: Lerociclib (DB16218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study: NCT05712941
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study: NCT06568445
Drug: Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
Study: NCT06440473
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 0.3% cream
Study: NCT05111860
Drug: Bevacizumab+mFOLFOX6
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
Study: NCT06568445
Drug: as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
Study: NCT04752267
Drug: 18F-FMAU
Normalized name: 18F-FMAU
DrugBank: 5-methyl-2'-fluoroarauracil F-18 (DB14913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06039280
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
Study: NCT06444997
Drug: Oxycodone Hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
Study: NCT05477615
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
Study: NCT05477615
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
Study: NCT05477615
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: - Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
Study: NCT05971680
Drug: VITAMIN B1 500mg
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VITAMIN B1 (High Potency) 500mg tab every day for 3 months
Study: NCT04796714
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One sachet of aspirin 160 mg per day during 3 months
Study: NCT04706715
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
Study: NCT06058988
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
Study: NCT05815004
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
Study: NCT03689114
Drug: Low dose carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine, 300 mg/die
Study: NCT03689114
Drug: Standard dose carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine 600 mg/die
Study: NCT03689114
Drug: Low dose levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 500 mg/die
Study: NCT03689114
Drug: Standard dose levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 1000 mg/die
Study: NCT03689114
Drug: Low dose valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate 300 mg/die
Study: NCT03689114
Drug: Standard dose valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate 600 mg/die
Study: NCT03689114
Drug: Low dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 150 mg/die
Study: NCT03689114
Drug: Standard dose zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 300 mg/die
Study: NCT03689114
Drug: Low dose topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 100 mg/die
Study: NCT03689114
Drug: Standard dose topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 200 mg/die
Study: NCT05198817
Drug: SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
Study: NCT03689114
Drug: Low dose lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 100 mg/die
Study: NCT03689114
Drug: Standard dose lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 200 mg/die
Study: NCT03689114
Drug: Low dose gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 450 mg/die
Study: NCT03689114
Drug: Standard dose gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 900 mg/die